Ethics and Compliance Associate - ANZ at Eli Lilly and Company

Sydney, New South Wales, Australia

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, PharmaceuticalsIndustries

Requirements

2-3 years’ experience in pharmaceutical industry, with familiarity of sales/marketing practices
Demonstrated ability to influence stakeholders at least one level above your role
Familiarity with the Medicines Australia Code of Conduct and Medicines New Zealand Code of Practice, or willingness to rapidly develop expertise in NZ pharmaceutical compliance
Ability to build strong relationships with internal & external stakeholders/business partners and broader Ethics and Compliance Team
Ability to interpret and apply compliance/code requirements and make them understandable to the business
Ability to manage conflict in an open and constructive manner
Effective communication, influence, negotiation, and critical thinking skills
Data analytics skill
Consistent compliance with regulatory and organizational requirements over the past 36 months, including adherence to relevant laws, company policies/procedures, and ethical standards in previous roles or professional activities

Responsibilities

Uphold adherence to internal policies and procedures, including the Medicines Australia Code of Conduct and the Medicines New Zealand Code of Practice
Proactively assess and communicate compliance risks across the business
Support the affiliate Ethics & Compliance training program and related communications, including updates on the MA/NZ Codes, newsletters, case studies, ChatBot initiatives, and E&C Advocates meetings
Execute approximately 70% of the annual monitoring plan for ANZ and deliver data analytics to support the Ethics & Compliance Manager in monitoring new initiatives and channels, including Telehealth, Lilly Direct, RxPx, HCI, B2B, consumer engagement, and pharmacy partnerships
Lead development and implementation of preventive and corrective action (CAPA) strategies, ensuring timely closure and re-monitoring of critical findings
Deliver timely, practical guidance in response to Ethics & Compliance consults from business stakeholders
Support monitoring, reporting, and training activities for NZ operations in line with Medicines NZ Code requirements
Support and act as a backup to the Ethics and Compliance Manager in leading periodic localisation and off-cycle reviews of procedures and job aids
Partner with business process owners to ensure compliance is embedded in workflows for new launches, expanded initiatives, and evolving business models
Monitor and assess compliance risks associated with business expansion, new channels, and partnerships
Manage and enhance the ANZ Ethics & Compliance SharePoint site and support the implementation of the 7 Elements framework
Serve as Departmental Records and Information Management (DRIM) steward for the E&C department

Skills

Ethics and Compliance

Risk Assessment

Compliance Training

Data Analytics

CAPA

Medicines Australia Code

Medicines New Zealand Code

Monitoring

Telehealth

Stakeholder Guidance

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free